Munich, DE – The global life-science community is gearing up for a landmark week in Munich this December, as two premier events by hubXchange spotlight cutting-edge innovations in therapeutic development:

Antibody Therapeutics Xchange – Europe 2025 on Monday 1st December 2025
Oligonucleotides & Peptides Xchange – Europe 2025 on Tuesday 2nd December 2025

Both events will take place at the Hilton Munich Airport Hotel (Terminalstraße Mitte 20, 85356 München-Flughafen, Germany).

---

Unlocking the Next Generation of Biotherapeutics

Antibody Therapeutics Xchange – Europe 2025 brings together senior-level scientists and executives from pharma and biotech to explore the full spectrum of therapeutic antibody development — from target selection and mechanisms of action to novel formats, scaffolds, bispecifics/multispecifics, and the exciting frontier of AI and machine learning in antibody discovery.

Attendees will have direct access to:

• Keynotes and spotlight presentations by leading experts

• Roundtable discussions designed for collaboration

• Pre-booked 1:1 meetings and networking sessions built into the agenda for maximum engagement

Whether you’re advancing a monoclonal program, pioneering bispecific platforms or harnessing AI-driven antibody discovery, this one-day event offers a high-impact environment to accelerate progress.

---

Charting Innovation in Oligonucleotides & Peptides

On Tuesday 2nd December, Oligonucleotides & Peptides Xchange – Europe 2025 shifts focus to the fast-moving world of RNA therapeutics, peptide design and delivery, and process development for next-gen modalities.

Highlights include sessions on:

• Emerging RNA modalities (antisense, siRNA, circular RNA)

• Advanced drug delivery systems, including lipid nanoparticles and novel chemistries

• CMC and process development challenges as oligonucleotide drugs scale toward GMP manufacturing

It’s a unique opportunity for biotech innovators, CDMOs, formulation scientists and functional leaders to converge, exchange ideas and catalyse new partnerships.

---

Why Attend?

• High-calibre networking: Engage directly with C-suite and senior decision-makers across discovery, development and manufacturing.

• Innovative agenda: Both events offer agenda tracks tailored to the most pressing challenges in biologics and oligonucleotide therapeutics.

• Collaborative format: Designed by hubXchange to maximise interaction, pre-booked meetings and small-group discussions elevate the value far beyond a typical conference.

• Cost-free for senior pipeline holders: Complimentary registration is available for senior-level scientists in pharma & biotech with an active drug pipeline.

---

Quote from hubXchange's Founder & Managing Director

“What makes hubXchange events truly unique is the depth of interaction we foster. Instead of passive presentations, we create environments where experts can exchange ideas, challenge assumptions and uncover new opportunities for collaboration. Munich will bring together some of Europe’s brightest scientific minds to push the boundaries of antibody and oligonucleotide innovation.”

— Clarence Maguire-Swartz, Founder & Managing Director, hubXchange

---

Registration & Contact

Secure your place today:

🟡Antibody Therapeutics Xchange – Register Here
🟠Oligonucleotides & Peptides Xchange – Register Here

For partnership or media enquiries, please contact:
Tel: +44 755 247 3356
Email: nathan@hub‐xchange.com

---

About hubXchange

hubXchange specialises in delivering high-level content, intelligence and connections to the global life-sciences community by hosting world-class business Xchanges.

Prepare to accelerate your therapeutic pipeline and forge the collaborations that will define the next era of biologics and nucleic-acid drug development.